NEW DELHI: Dr Reddy’s Laboratories on Thursday said its consolidated net profit increased 2 per cent to Rs 1,413 crore in the third quarter ended December 31, 2024 driven by robust performance across markets. The Hyderabad-based drug major had reported a profit of Rs 1,379 crore for the October-December period of last fiscal.
Revenue increased to Rs 8,359 crore from Rs 7,215 crore a year ago, Dr Reddy’s Laboratories said in a statement.
“We delivered double-digit growth aided by our newly acquired NRT business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation,” company’s Co-Chairman & MD G V Prasad said.
The company said its revenues in the US market increased by 1 per cent year-on-year to Rs 3,383 crore in the third quarter.
Sales in India rose to Rs 1,346 crore from Rs 1,180 crore in the same period last fiscal, a growth of 14 per cent.
Similarly, sales in Europe grew to Rs 1,210 crore as compared with Rs 497 crore in December quarter last fiscal.
Sales in emerging markets grew 12 per cent year-on-year to Rs 1,436 crore.
Dr Reddy’s shares on Thursday ended 0.54 per cent down at Rs 1,289.35 apiece on BSE.
